• Diet may affect colon cancer outcomes

    4 monthes ago - By Healio

    A diet with a high insulin load increased risk for colon can recurrence and mortality, according to results of a prospective, observational study.
    Thus, dietary factors may play a role in colon cancer recurrence and survival following resection.
    “We now have evidence that may help avoid a recurrence of the disease and improve their prospects of survival by following a healthy diet,” Vicente Morales-Oyarvide, MD, MPH, from the department of medicine at DanaFarber Cancer Institute, said in a press release. “These research results should be empowering to this group of
    Read more ...

     

  • VIDEO: Lenvatinib-pembrolizumab shows promise in several cancer types

    4 monthes ago - By Healio

    CHICAGO - Alton B. Kremer, MD, PhD, chief clinical officer and chief medical officer of the oncology business group at Eisai, spoke with HemOnc Today at ASCO Annual Meeting about key studies of agents in the company's pipeline.
    At ASCO, researchers presented data from studies designed to assess combination treatment with the multitargeted tyrosine kinase inhibitor lenvatinib and the anti-PD-1 monoclonal antibody pembrolizumab for treatment of patients with renal cell carcinoma, endometrial cancer, head and neck cancer, and hepatocellular
    Read more ...

     

  • Studies of immunotherapy for prostate cancer yield encouraging results

    4 monthes ago - By Healio

    Sumit K. Subudhi
    Several studies designed to investigate immunotherapies and immunotherapeutic combinations for treatment of prostate cancer have yielded encouraging results.
    Sumit K. Subudhi, MD, PhD, assistant professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center, and colleagues in MD Anderson's Prostate Cancer Moon Shot program are investigating immune-inhibitory pathways in the prostate cancer microenvironment.
    They found that the tumor upregulates PD-L1 and VISTA inhibitory molecules in response to monotherapy with ipilimumab (Yervoy, Bristol
    Read more ...